Randomized Phase III Study on Bortezomib and Low-Dose Dexamethasone With or Without Continuous Low-Dose Oral Cyclophosphamide for Primary Refractory or Relapsed Multiple Myeloma
Phase of Trial: Phase III
Latest Information Update: 09 Dec 2014
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Cyclophosphamide
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Sponsors Janssen-Cilag
- 01 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Apr 2012 New source identifed and integrated (EudraCT2008-003213-27: European Clinical Trials Database).
- 16 Apr 2012 Actual patient number changed from 96 to 95 as reported by ClinicalTrials.gov.